Shchelkovsky Biokombinat, a key manufacturer of veterinary drugs in Russia, has been implementing an import substitution program for more than five years. During this time, the company has not only fully localized the production of critically important vaccines, but also launched a line of drugs on the market, the press service of the Ministry of Agriculture and Food of the Moscow Region reports.
"Over the past five years, the plant has developed and introduced about 12 new vaccines into production, which has increased their output by more than 3.5 times. The company's dynamic development continues: currently, more than 10 new drugs are under active development. Some of them are already undergoing the state registration procedure, and a number more are at the stage of preclinical and clinical trials. Some promising projects are being implemented in cooperation with scientific and industry partners. Today, the company supplies vaccines and other veterinary medicines to more than 20 countries around the world. To further expand the geography of exports, the product registration procedure has now been initiated in six more countries," the report says.
Shchelkovsky Biocombinat is located in the Moscow region and is one of the largest enterprises in Russia for the development and production of medicines and preparations for veterinary use. The plant has a full production cycle, from scientific research to mass production of finished products. The main activity is aimed at ensuring the biological safety and health of agricultural, domestic and wild animals.
Please note that this press release is based on materials provided by the company. AK&M Information Agency shall not be held liable for its contents, nor for the legal and other consequences of its publication.
